Roland B. Walter
M.S., University of Washington, Epidemiology (Clinical Research), 2011.
Ph.D., University of Washington, Experimental Pathology, 2006.
M.D., University of Zurich, Medicine, 1997.
Dr. Walter's laboratory research is focused on human acute myeloid leukemia (AML), in particular on the delineation of the clonal origin of AML, the molecular and phenotypic characterization of AML stem and progenitor cells, and the interaction between AML cells in their environment. A long-term goal of his preclinical studies is the development of novel therapeutic strategies aimed to eradicate AML stem and progenitor cells. Findings from such studies are then translated into the clinic and tested in early phase human trials.
A second research interest of Dr. Walter is the development and conduct of clinical trials in AML. Dr. Walter is currently the Principal Investigator of several early phase clinical trials that test new drugs and drug combinations in AML; he also leads a phase 2 study that explores a strategy of outpatient management of selected AML/MDS patients following intensive induction chemotherapy.
(Reading, Writing, Speaking)
English: (Fluent, Fluent, Fluent)
German: (Fluent, Fluent, Fluent)
Schwyzerdutsch: (Fluent, Fluent, Fluent)
American Society of Hematology
Honors and Awards
2009-2012, Mentored Patient-Oriented Research Career Development Award (K23), National Cancer Institute, National Institutes of Health (NIH), National Institute of Health (NIH)
2006-2009, Special Fellow Career Development Award, Leukemia & Lymphoma Society
2005, SIAK/ESSEX Award in Applied Cancer Research Switzerland
2005, Dr. Ernst Th. Jucker Price for Cancer Research Switzerland
2005-2007, Clinical/Translational Research Scholar Award, American Society of Hematology
2005-2005, Career Development Award, Janggen-Pohn Foundation, Switzerland
2004-2004, Interdisciplinary Dual Mentor Fellowship, Fred Hutchinson Cancer Research Center
2002-2004, Fellowship for Advanced Researchers, Swiss Foundation for Medical-Biological Grants
2008-2010, Research Associate, Fred Hutchinson Cancer Research Center, Clinical Research Division
2008-2010, Acting Instructor in Medicine, University of Washington, Department of Medicine, Division of Hematology
2005-2007, Fellow, University of Washington, Department of Medicine, Division of Hematology
2002-2008, Post-Doctoral Research Fellow, Fred Hutchinson Cancer Research Center, Clinical Research Division
1999-2002, Resident, University of Zurich, Department of Medicine
1997-1999, Resident, Kantonsspital Chur, Department of Medicine
1996-1997, Research Fellow, University of Zurich, Department of Medicine
Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(6):1620-1627.. 2013.
High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Leukemia & lymphoma. 54(1):202-204.. 2013.
Mott cells.. European journal of haematology. 90(1):83.. 2013.
Myeloid sarcoma of the heart.. Leukemia & lymphoma.. 2012.
Vitamin, Mineral, and Specialty Supplements and Risk of Hematologic Malignancies in the Prospective VITamins And Lifestyle (VITAL) Study.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 20(10):2298-308.. 2011.
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(33):4417-24.. 2011.
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(9):1190-7.. 2011.
Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(17):2424-31.. 2011.
Cancer Risk Associated with Long-term Use of Acetaminophen in the Prospective VITamins and Lifestyle Study.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 20(12):2637-2641.. 2011.
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.. Blood. 116(14):2420-8.. 2010.
High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(17):2831-8.. 2010.
Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 24(7):1276-82.. 2010.
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(10):1766-71.. 2010.
Pretargeted radioimmunotherapy for hematologic and other malignancies.. Cancer biotherapy & radiopharmaceuticals. 25(2):125-42.. 2010.
ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2.. Journal of leukocyte biology. 83(1):200-11.. 2008.
Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor.. Traffic (Copenhagen, Denmark). 9(2):267-79.. 2008.